Edwards Lifesciences Corp. shares fall 17% as it lowers TAVR sales outlook to 5%-7%, acquires JenaValve Technology and Endotronix for $1.
Edwards Lifesciences Corp. shares dropped 17% after lowering its sales outlook for its transcatheter aortic heart-valve replacement (TAVR) unit to 5%-7% growth, down from 8%-10%. The company also announced plans to acquire JenaValve Technology and Endotronix for $1.2bn to address unmet needs for aortic regurgitation and heart failure patients. The acquisitions are expected to close in 2025.
July 24, 2024
3 Articles